Select a medication above to begin.
Hemlibra (emicizumab-kxwh)
emicizumab
Black Box Warnings .
Thrombotic Microangiopathy and Thromboembolism
cases reported when activated prothrombin complex concentrate (aPCC) was given >100 units/kg/24h for >24h; monitor for s/sx of thrombotic microangiopathy and thrombotic events if aPCC is given; D/C aPCC and hold emicizumab if s/sx occur
Adult Dosing .
Dosage forms: INJ: 12 mg per 0.4 mL, 30 mg per mL, 60 mg per 0.4 mL, 105 mg per 0.7 mL, 150 mg per mL, 300 mg per 2 mL
Special Note
- [formulation clarification]
- Info: nonproprietary name = emicizumab-kxwh
routine bleeding prophylaxis, hemophilia A
- [1.5 mg/kg/dose SC qwk]
- Start: 3 mg/kg/dose SC qwk x4wk; Alt: 3 mg/kg/dose SC q2wk; 6 mg/kg/dose SC q4wk; Info: D/C prophylactic use of bypassing agents 24h before 1st dose; may overlap w/ prophylactic use of factor VIII up to 1wk
renal dosing
- [see below]
- CrCl >30: no adjustment; CrCl <30: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- bilirubin 1-3x ULN: no adjustment; bilirubin >3x ULN: not defined
Peds Dosing .
- Dosage forms: INJ: 12 mg per 0.4 mL, 30 mg per mL, 60 mg per 0.4 mL, 105 mg per 0.7 mL, 150 mg per mL, 300 mg per 2 mL
Special Note
- [formulation clarification]
- Info: nonproprietary name = emicizumab-kxwh
routine bleeding prophylaxis, hemophilia A
- [1.5 mg/kg/dose SC qwk]
- Start: 3 mg/kg/dose SC qwk x4wk; Alt: 3 mg/kg/dose SC q2wk; 6 mg/kg/dose SC q4wk; Info: D/C prophylactic use of bypassing agents 24h before 1st dose; may overlap w/ prophylactic use of factor VIII up to 1wk
renal dosing
- [see below]
- CrCl >30: no adjustment; CrCl <30: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- bilirubin 1-3x ULN: no adjustment; bilirubin >3x ULN: not defined